QV Investors Inc. Sells 68,250 Shares of Solventum Co. (NYSE:SOLV)

QV Investors Inc. lessened its position in Solventum Co. (NYSE:SOLV) by 27.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 182,312 shares of the company’s stock after selling 68,250 shares during the quarter. Solventum accounts for 1.2% of QV Investors Inc.’s portfolio, making the stock its 29th largest position. QV Investors Inc. owned about 0.11% of Solventum worth $12,044,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Victory Capital Management Inc. bought a new position in shares of Solventum during the 2nd quarter worth $1,194,000. Private Advisor Group LLC purchased a new position in Solventum during the 2nd quarter valued at about $1,139,000. Los Angeles Capital Management LLC bought a new stake in shares of Solventum in the 2nd quarter valued at about $281,000. Acadian Asset Management LLC purchased a new stake in shares of Solventum in the 2nd quarter worth approximately $1,774,000. Finally, Texas Permanent School Fund Corp bought a new position in shares of Solventum during the second quarter valued at approximately $1,187,000.

Solventum Price Performance

NYSE SOLV traded up $1.10 during trading hours on Monday, reaching $68.17. The stock had a trading volume of 363,149 shares, compared to its average volume of 1,056,485. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock has a fifty day moving average of $69.32 and a 200 day moving average of $65.00.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on SOLV shares. Mizuho assumed coverage on Solventum in a research note on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective for the company. Morgan Stanley lifted their price objective on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. Piper Sandler raised their target price on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Stifel Nicolaus initiated coverage on shares of Solventum in a report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price target on the stock. Finally, Wolfe Research assumed coverage on Solventum in a report on Thursday, September 26th. They set a “peer perform” rating for the company. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.